Mölnlycke Health Care, a world-leading provider of high-quality healthcare solutions, announces the acquisition of Sundance Solutions, a leader in developing innovative solutions for the safe positioning and turning of patients to help prevent pressure ulcers.
Sundance’s proprietary solutions include Tortoise™, a unique and simple turning, positioning and offloading system that is easy to use, safe for both patients and caregivers. Together with its fluidized media technology, they complement Mölnlycke’s portfolio of advanced dressing solutions – offering clinicians a more complete and unique range of tools to ensure better patient outcomes. Sundance’s annual revenues amount to approximately $25 million.
The acquisition will combine the distinctive and complementary strengths of two innovators in the field of pressure ulcer prevention – delivering unique value for healthcare professionals and providers.
Richard Twomey, CEO, Mölnlycke Health Care says, “We are very enthusiastic about joining forces with Sundance Solutions, thereby taking a huge step forward to help patients, their families, and caregivers prevent pressure ulcers. Pressure ulcers represent a huge burden of sickness and reduced quality of life for patients, and they are a major challenge for clinicians. At a time when healthcare providers are pressed to both reduce costs and maintain and improve patient care, Mölnlycke is committed to help them achieve both better patient outcomes and financial savings.”
William Purdy, CEO of Sundance Solutions commenta, “We are delighted to join Mölnlycke Health Care as a recognized global leader in medical devices that shares our company values. We are very happy that our unique line of pressure ulcer prevention products will now be available through a trusted industry pioneer such as Mölnlycke.”
Pressure ulcers are a frequently-occurring, costly, avoidable side effect of patient care, affecting 2.5 million patients per year in the U.S. and costing up to $11.6 billion per year.(1) It is estimated that up to 30 percent of hospital patients, as well as 20 percent of patients in nursing and residential homes, may suffer from the condition.(2) The cost of individual patient care can range from $20,000 to $150,000 per pressure ulcer.(1)
For several years Mölnlycke Health Care has contributed to the prevention of pressure ulcers through its range of advanced dressing solutions with Safetac®. The results of more than 30 clinical and economic studies, including data from randomized controlled trials, demonstrate that the use of multi-layer foam dressings with Safetac® – such as Mepilex® Border Sacrum and Mepilex® Border Heel – can reduce the occurrence of pressure ulcers as a component of standard preventive measures.(3)
References
1. Agency for Healthcare Research and Quality. Preventing pressure ulcers in hospitals. www.ahrq.gov/professionals/systems/hospital/pressureulcertoolkit/putool1.html
2. NHS Institute for Innovation and Improvement. Your skin matters. www.institute.nhs.uk/building_capability/general/your_skin_matters.html
3. Davies P. Role of multi-layer foam dressings with Safetac in the prevention of pressure ulcers: a review of the clinical and scientific data. Journal of Wound Care 2016; 25(1): S1-S24
Source: Mölnlycke Health Care
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.